TY - JOUR
T1 - Assessing mobility in primary brain tumor patients
T2 - A descriptive feasibility study using two established mobility tests
AU - Rogers, James L.
AU - De La Cruz Minyety, Julianie
AU - Vera, Elizabeth
AU - Acquaye, Alvina A.
AU - Payén, Samuel S.
AU - Weinberg, Jeffrey S.
AU - Armstrong, Terri S.
AU - Weathers, Shiao Pei S.
N1 - Publisher Copyright:
© 2022 Published by Oxford University Press 2022.
PY - 2022/5/1
Y1 - 2022/5/1
N2 - Background: Patients with primary brain tumors (PBT) face significant mobility issues related to their disease and/or treatment. Here, the authors describe the preliminary utility and feasibility of two established mobility measures, the Timed-Up-and-Go (TUG) and Five-Times Sit-to-Stand (TSS) tests, in quickly and objectively assessing the mobility status of PBT patients at a single institution's neuro-oncology clinic. Methods: Adult patients undergoing routine PBT care completed the TUG/TSS tests and MD Anderson Symptom Inventory-Brain Tumor module (MDASI-BT), which assessed symptom burden and interference with daily life, during clinic visits over a 6-month period. Research staff assessed feasibility metrics, including test completion times/rates, and collected demographic, clinical, and treatment data. Mann-Whitney tests, Kruskal-Wallis tests, and Spearman's rho correlations were used to interrogate relationships between TUG/TSS test completion times and patient characteristics. Results: The study cohort included 66 PBT patients, 59% male, with a median age of 47 years (range: 20-77). TUG/TSS tests were completed by 62 (94%) patients. Older patients (P <. 001) and those who were newly diagnosed (P =. 024), on corticosteroids (P =. 025), or had poor (≤80) KPS (P <. 01) took longer to complete the TUG/TSS tests. Worse activity-related (work, activity, and walking) interference was associated with longer TUG/TSS test completion times (P <. 001). Conclusions: The TUG/TSS tests are feasible for use among PBT patients and may aid in clinical care. Older age, being newly diagnosed, using corticosteroids, poor (≤80) KPS, and high activity-related interference were associated with significant mobility impairment, highlighting the tests' potential clinical utility. Future investigations are warranted to longitudinally explore feasibility and utility in other practice and disease settings.
AB - Background: Patients with primary brain tumors (PBT) face significant mobility issues related to their disease and/or treatment. Here, the authors describe the preliminary utility and feasibility of two established mobility measures, the Timed-Up-and-Go (TUG) and Five-Times Sit-to-Stand (TSS) tests, in quickly and objectively assessing the mobility status of PBT patients at a single institution's neuro-oncology clinic. Methods: Adult patients undergoing routine PBT care completed the TUG/TSS tests and MD Anderson Symptom Inventory-Brain Tumor module (MDASI-BT), which assessed symptom burden and interference with daily life, during clinic visits over a 6-month period. Research staff assessed feasibility metrics, including test completion times/rates, and collected demographic, clinical, and treatment data. Mann-Whitney tests, Kruskal-Wallis tests, and Spearman's rho correlations were used to interrogate relationships between TUG/TSS test completion times and patient characteristics. Results: The study cohort included 66 PBT patients, 59% male, with a median age of 47 years (range: 20-77). TUG/TSS tests were completed by 62 (94%) patients. Older patients (P <. 001) and those who were newly diagnosed (P =. 024), on corticosteroids (P =. 025), or had poor (≤80) KPS (P <. 01) took longer to complete the TUG/TSS tests. Worse activity-related (work, activity, and walking) interference was associated with longer TUG/TSS test completion times (P <. 001). Conclusions: The TUG/TSS tests are feasible for use among PBT patients and may aid in clinical care. Older age, being newly diagnosed, using corticosteroids, poor (≤80) KPS, and high activity-related interference were associated with significant mobility impairment, highlighting the tests' potential clinical utility. Future investigations are warranted to longitudinally explore feasibility and utility in other practice and disease settings.
KW - clinical cancer research
KW - clinical observations
KW - mobility assessment
KW - symptoms
UR - http://www.scopus.com/inward/record.url?scp=85133579232&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85133579232&partnerID=8YFLogxK
U2 - 10.1093/nop/npac013
DO - 10.1093/nop/npac013
M3 - Article
C2 - 35601968
AN - SCOPUS:85133579232
SN - 2054-2577
VL - 9
SP - 219
EP - 228
JO - Neuro-Oncology Practice
JF - Neuro-Oncology Practice
IS - 3
ER -